PeptiSystems raises 20 MSEK through directed share issue
PeptiSystems AB, a leading innovator within the oligonucleotide and peptide instrument process sector, is pleased to announce the successful closure of its latest investment round through a new directed emission of stocks. This strategic move represents a significant milestone for the company and underscores its commitment to growth and innovation.
The investment round attracted enthusiastic participation from both existing and new investors, highlighting the strong confidence in Peptisystems' products and market potential. The funds raised will be utilized to fuel Peptisystems's expansion efforts, accelerate product development, and further solidify its position as a key player in the oligonucleotide and peptide process instrument sector.
"We are thrilled to have concluded this investment round of 20 MSEK, which demonstrates the strong support from our investors," said CEO, Karin Granath. "The raised capital will empower us to scale our operations, ultimately driving enhanced value for our customers and stakeholders. We are happy to have new strong investors on board, Henrik Didner through Monesi Förvaltning AB and Nolsterby Invest AB, together with continued support from our existing investors Almi Invest and PÄAB.“
PeptiSystems, a start-up company renowned for successfully being able to transfer the flow-through column technology into the peptide manufacturing process field, will use this latest investment to amplify the company's operational capabilities to meet the growing market demands and capitalize on emerging opportunities. By securing this round of funding, PeptiSystems is well-positioned to strengthen its market presence and continue its trajectory of success.
”We got excellent traction in our sales during 2022, reaching profitability”, said Mats Johnson, Chairman of the Board. ”With the new capital, we can much better capture the opportunity that we see in the market and enhance our growth rate, thus our value creation.”
For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
Email: karin.granath@peptisystems.com
About PeptiSystems AB
PeptiSystems is a biotech company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilizing proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.